Abstract:Background A combination of ipratropium bromide (IB) and salbutamol is commonly used to treat asthma in children and adolescents; however, there has been a lack of consistency in its usage in clinical practice. Objective To evaluate the efficacy and safety of IB + salbutamol in the treatment of asthma in children and adolescents. Methods The MEDLINE, Embase, and Cochrane Library as well as other Chinese biomedical databases (including China Biological Medicine Database, Chinese National Knowledge Infrastructure, Chongqing VIP, and Wanfang Chinese language bibliographic database) were systematically searched from the earliest record date to September 2020 for randomized controlled trials in children and adolescents (≤18 years) with asthma who received IB + salbutamol or salbutamol alone. The primary outcomes included hospital admission and adverse events. A random effects model with a 95% confidence interval (CI) was used. Subgroup analysis was performed according to age, severity of asthma, and co-interventions with other asthma controllers. This study was registered with PROSPERO. Results Of the 1061 studies that were identified, 55 met the inclusion criteria and involved 6396 participants. IB + salbutamol significantly reduced the risk of hospital admission compared with salbutamol alone (risk ratio [RR] 0.79; 95% CI 0.66–0.95; p = 0.01; I 2 = 40%). Subgroup analysis only showed significant difference in the risk of hospital admission in participants with severe asthma exacerbation (RR 0.73; 95% CI 0.60–0.88; p = 0.0009; I 2 = 4%) and moderate-to-severe exacerbation (RR 0.69; 95% CI 0.50–0.96; p = 0.03; I 2 = 3%). There were no significant differences in the risk of adverse events between IB + salbutamol group and salbutamol alone group (RR 1.77; 95% CI 0.63–4.98). Conclusion IB + salbutamol may be more effective than salbutamol alone for the treatment of asthma in children and adolescents, especially in those with severe and moderate to severe asthma exacerbation. The very low to high quality of evidence indicated that future well-designed double-blind RCTs with large sample are needed for research on evaluating the effectiveness of IB + salbutamol treatment for asthma in children and adolescents.

The combination therapy of bronchial asthma in children

Successful Treatments For Allergic Bronchopulmonary Aspergillosis In Non-Cystic Fibrosis Children: A Report Of Two Cases And A Literature Review

Some Problems in Control Therapy of Asthma in Children

Combination therapy of long-acting beta2-adrenoceptor agonists and corticosteroids for asthma

Mechanism of allergen specific immunotherapy and its influence on lung function in asthma children

Treatment efficacy evaluation of standardized management for children with asthma

Advances in Asthma Treatment

Optimal use of control medication for childhood asthma

Advances in Pulmonary Rehabilitation for Children with Bronchial Asthma.

Treatment of Pediatric Mild Persistent Asthma with Low-Dose Budesonide Inhalation Suspension Vs.montelukast in China

Application of Asthma Predictive Index-Based Group Therapy in Wheezing Children under 5 Years of Age

Effectiveness of Drug Treatment Strategies to Prevent Asthma Exacerbations and Increase Symptom-Free Days in Asthmatic Children: A Network Meta-Analysis

Combination of ipratropium bromide and salbutamol in children and adolescents with asthma: A meta-analysis

Treatment of chronic moderate asthma by corticosteroid inhalation with controlled released theophylline or beta2-agonist

The Comparison of Clinical Features in Children with Different Control Levels of Asthma

Research Progress in Integrated Chinese and Western Medicine Health Management for School-Age Children with Asthma

Approach to difficult-to-treat asthma in childhood: a narrative review

Budesonide in Combination with Salbutamol in the Treatment of 61 Cases of Childhood Bronchial Asthma During Acute Episodes

Evaluation and Treatment of Critical Asthma Syndrome in Children

Highlights of bronchial asthma in children guideline (2016 edition) for its diagnosis and treatment

Combined treatment with ipratropium bromide and beta-2-adrenoceptor agonists in childhood asthma